Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome.
Guohua Song, Min Li, Hui Sang, Liying Zhang, Xiuhong Li, Shutong Yao, Yang Yu, Chuanlong Zong, Yazhuo Xue, Shucun Qin · Journal of lipid research · 2013
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 0 patients with potential metabolic syndrome, serum analysis showed that consumption of H₂-rich water for 10 weeks resulted in decreased serum total-cholesterol (TC) and LDL-cholesterol (LDL-C) levels. These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 0 patients with potential metabolic syndrome. Serum analysis showed that consumption of H₂-rich water for 10 weeks resulted in decreased serum total-cholesterol (TC) and LDL-cholesterol (LDL-C) levels.
What the Researchers Studied
The researchers studied 0 patients with potential metabolic syndrome. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen exposure: 1 L hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂. Serum analysis showed that consumption of H₂-rich water for 10 weeks resulted in decreased serum total-cholesterol (TC) and LDL-cholesterol (LDL-C) levels. The authors concluded that in conclusion, supplementation with H₂-rich water seems to decrease serum LDL-C and apoB levels, improve dyslipidemia-injured HDL functions, and reduce oxidative stress, and it may have a beneficial role in prevention of potential metabolic syndrome.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 0 patients with potential metabolic syndrome. The reported sample size was 20. The study used a human clinical study. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen exposure was 1 L hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.